Phase II study of eribulin mesylate (E7389) in patients with metastatic castration-resistant prostate cancer stratified by prior taxane therapy

Treatment options remain limited for patients with castration-resistant prostate cancer (CRPC). We evaluated eribulin mesylate (E7389), a nontaxane halichondrin B analog microtubule inhibitor, in patients with metastatic CRPC with or without previous taxane exposure. Men with histologically proven C...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Annals of oncology 2012-05, Vol.23 (5), p.1241-1249
Hauptverfasser:	de Bono, J.S., Molife, L.R., Sonpavde, G., Maroto, J.P., Calvo, E., Cartwright, T.H., Loesch, D.M., Feit, K., Das, A., Zang, E.A., Wanders, J., Agoulnik, S., Petrylak, D.P.
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Aged, 80 and over Algorithms Antineoplastic agents Antineoplastic Agents - adverse effects Antineoplastic Agents - therapeutic use Biological and medical sciences Carcinoma - drug therapy Carcinoma - pathology Carcinoma - surgery castrate-resistance chemotherapy Chemotherapy, Adjuvant Drug Resistance, Neoplasm - drug effects eribulin mesylate Furans - adverse effects Furans - therapeutic use Gynecology. Andrology. Obstetrics Humans Ketones - adverse effects Ketones - therapeutic use Male Male genital diseases Medical sciences microtubule inhibitor Middle Aged Neoplasm Metastasis Nephrology. Urinary tract diseases Orchiectomy Patient Selection Pharmacology. Drug treatments prostate cancer prostate-specific antigen Prostatic Neoplasms - drug therapy Prostatic Neoplasms - pathology Prostatic Neoplasms - surgery Taxoids - therapeutic use Treatment Failure Treatment Outcome Tumors Tumors of the urinary system Urinary tract. Prostate gland
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!